Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
de Meza, Melissa M., Ismail, Rawa K., Rauwerdink, Daan, van Not, Olivier J., van Breeschoten, Jesper, Blokx, Willeke A.M., de Boer, Anthonius, van Dartel, Maaike, Hilarius, Doranne L., Ellebaek, Eva, Bonenkamp, Han J., Blank, Christian U., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., de Groot, Jan Willem B., Haanen, John B., Hospers, Geke A.P., Kapiteijn, Ellen W., Piersma, Djura, van Rijn, Roos S., van der Veldt, Astrid A.M., Vreugdenhil, Art, Westgeest, Hans M., van den Eertwegh, Alfons J.M., Suijkerbuijk, Karijn P.M., Wouters, Michel W.J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 158, 234-245. ELSEVIER SCI LTD
European Journal of Cancer, 158, 234-245. Elsevier Ltd.
European Journal of Cancer, 158, 234. Elsevier Ltd
European Journal of Cancer, 158, 234-245
de Meza, M M, Ismail, R K, Rauwerdink, D, van Not, O J, van Breeschoten, J, Blokx, W A M, de Boer, A, van Dartel, M, Hilarius, D L, Ellebaek, E, Bonenkamp, H J, Blank, C U, Aarts, M J B, van Akkooi, A C J, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, A, Westgeest, H M, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2021, ' Adjuvant treatment for melanoma in clinical practice – Trial versus reality ', European Journal of Cancer, vol. 158, pp. 234-245 . https://doi.org/10.1016/j.ejca.2021.08.044
European Journal of Cancer, 158, pp. 234-245
European Journal of Cancer, 158, 234-245. Pergamon
European Journal of Cancer, 158, 234-245. Elsevier Ltd.
European Journal of Cancer, 158, 234. Elsevier Ltd
European Journal of Cancer, 158, 234-245
de Meza, M M, Ismail, R K, Rauwerdink, D, van Not, O J, van Breeschoten, J, Blokx, W A M, de Boer, A, van Dartel, M, Hilarius, D L, Ellebaek, E, Bonenkamp, H J, Blank, C U, Aarts, M J B, van Akkooi, A C J, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, A, Westgeest, H M, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2021, ' Adjuvant treatment for melanoma in clinical practice – Trial versus reality ', European Journal of Cancer, vol. 158, pp. 234-245 . https://doi.org/10.1016/j.ejca.2021.08.044
European Journal of Cancer, 158, pp. 234-245
European Journal of Cancer, 158, 234-245. Pergamon
Background: Little is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have been registered in the DMTR, a population-based registry to monitor the quality an
Autor:
de Weger, Vincent A, Stuurman, Frederik E, Hendrikx, Jeroen J M A, Moes, Johannes J, Sawicki, Emilia, Huitema, Alwin D R, Nuijen, Bastiaan, Thijssen, Bas, Rosing, Hilde, Keessen, Marianne, Mergui-Roelvink, Marja, Beijnen, Jos H, Schellens, Jan H M, Marchetti, Serena, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European Journal of Cancer, 86, 217. Elsevier Limited
European Journal of Cancer, 86, 217. Elsevier Ltd
European Journal of Cancer, 86, 217. Elsevier Ltd
Introduction Two solid dispersions of docetaxel (denoted ModraDoc001 capsule and ModraDoc006 tablet (both 10 mg)) were co-administered with 100 mg ritonavir (/r) and investigated in a bi-daily once weekly (BIDW) schedule. Safety, maximum tolerated do